leadf
logo-loader
viewFSD Pharma

FSD Pharma CFO bolsters World Class Extractions team

It was announced FSD Pharma CFO Donal Carroll will join the board of directors or management of World Class Extractions Inc

1550185087_shutterstock_283236740.jpg
Carroll has over 15 years of corporate finance leadership and public company experience

FSD Pharma Inc (CSE:HUGE) (OTCQB:FSDDF) chief financial officer Donal Carroll will join the board of directors or management of newly-announced World Class Extractions Inc, according to a statement put out Thursday. 

World Class is an Ontario-incorporated developer of a cannabis extraction process, which intends to provide single-step continuous-flow extraction services to the hemp and cannabis industries. 

READ: FSD Pharma and Canntab Therapeutics forge pact with World Class Extractions to strike hemp deal

Carroll has over 15 years of corporate finance leadership and public company experience, as well as in-depth experience in syndicated investments in equity and debt securities. Throughout his career with Danaher Corporation, Unilever plc, and Cardinal Meat Specialists Ltd, Carroll played roles in major restructuring activities, mergers and acquisitions, and the implementation of new internal controls and enterprise resource planning systems.

Shares of FSD Pharma were at C$0.27 on Thursday. 

Contact Katie Lewis at [email protected]

 

Quick facts: FSD Pharma

Price: 2.38 CAD

CSE:HUGE
Market: CSE
Market Cap: $45.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

FSD Pharma fully funded to continue progress on its Phase 2 study on...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) CEO Raza Bokhari tells Proactive the biopharma group is fully funded to continue progress on its Phase 2 study to treat hospitalized coronavirus patients. Bokhari says its most recent fundraising gives the firm $9.5M to conduct the trial, which will...

1 month, 1 day ago

2 min read